Breast cancer survivors who developed incident myocardial infarction or heart failure exhibited increased risk for adverse oncologic outcomes, according to a population-based cohort study.The findings ...

Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma, ...

Malignancy Spectrum, a cutting-edge journal dedicated to advancing the field of oncology, presents its latest issue, Volume 1, Issue 4. This issue ...

Skin Analytics Ltd. received CE mark for its AI-based tool Deep Ensemble for the Recognition of Malignancy (DERM), which can assess images of lesions and detect skin cancer autonomously. The ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

1 Laboratories of the Rockefeller Institute for Medical Research, N. Y., and the Department of Pathology, University of Virginia, University, Va.

Introduction: Malignancy represents an important subgroup of embolic stroke of undetermined source (ESUS). We aim to compare infarct features, potential embolic sources, and long-term outcomes in ESUS ...

ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that ...

Agilus Diagnostics, India’s diagnostic network, has introduced a three-day turnaround time (TAT) for test results in myeloid malignancies. This development comes as the genomic testing market in India ...

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase I drugs for Advanced Malignancy does not have ...